Cited by 174Peroxisome Proliferator-Activated ReceptorsNitric Oxide and Endothelin EffectsParaoxonase enzyme and polymorphisms

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Peroxisome Proliferator-Activated Receptor α Agonists Increase Nitric Oxide Synthase Expression in Vascular Endothelial Cells

Goya, Kayoko, Sumitani, Satoru, Xu, Xin, Kitamura, Tetsuhiro, Yamamoto, Hiroyasu, Kurebayashi, Shogo, Saito, Hiroshi, Kouhara, Haruhiko, Kasayama, Soji, Kawase, Ichiro·2004·Arteriosclerosis, Thrombosis, and Vascular Biology

DOI 10.1161/01.atv.0000118682.58708.78

Open this paper in CoChat — free account

Abstract

Objective— There has been accumulating evidence demonstrating that activators for peroxisome proliferator-activated receptor α (PPARα) have antiinflammatory, antiatherogenic, and vasodilatory effects. We hypothesized that PPARα activators can modulate endothelial nitric oxide synthase (eNOS) expression and its activity in cultured vascular endothelial cells. Methods and Results— Bovine aortic endothelial cells were treated with the PPARα activator fenofibrate. The amount of eNOS activity and the expression of eNOS protein and its mRNA were determined. Our data show that treatment with fenofibrate for 48 hours resulted in an increase in eNOS activity. Fenofibrate failed to increase eNOS activity within 1 hour. Fenofibrate also increased eNOS protein as well as its mRNA levels. RU486, which has been shown to antagonize PPARα action, inhibited the fenofibrate-induced upregulation of eNOS protein expression. WY14643 and bezafibrate also increased eNOS protein levels, whereas rosiglitazone did not. Transient transfection experiments using human eNOS promoter construct showed that fenofibrate failed to enhance eNOS promoter activity. Actinomycin D studies demonstrated that the half-life of eNOS mRNA increased with fenofibrate treatment. Conclusions— PPARα activators upregulate eNOS expression, mainly through mechanisms of stabilizing eNOS mRNA. This is a new observation to explain one of the mechanisms of PPARα-mediated cardiovascular protection.

Integrity signals

Registry

Crossref · 10.1161/01.atv.0000118682.58708.78

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A novel potent vasoconstrictor peptide produced by vascular endothelial cells
Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y. I., Kobayashi, M., Mitsui, Y., Yazaki, Y., Goto, K., & Masaki, T. (1988) · Nature · doi:10.1038/332411a0 · Cited by 10,716
The L-Arginine-Nitric Oxide Pathway
Epstein, F. H., Moncada, S., & Higgs, A. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312303292706 · Cited by 6,678
Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation
Dimmeler, S., Fleming, I., Fisslthaler, B., Hermann, C., Busse, R., & Zeiher, A. M. (1999) · Nature · doi:10.1038/21224 · Cited by 3,591
Regulation of endothelium-derived nitric oxide production by the protein kinase Akt
Fulton, D. J., Gratton, J., McCabe, T. J. D., Fontana, J. T., Fujio, Y., Walsh, K. X., Franke, T. F., Papapetropoulos, A., & Sessa, W. C. (1999) · Nature · doi:10.1038/21218 · Cited by 2,616
Roles of PPARs in health and disease
Kersten, S., Desvergne, B., & Wahli, W. (2000) · Nature · doi:10.1038/35013000 · Cited by 1,956
Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786
Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines.
Caterina, R. D., Libby, P., Peng, H., Thannickal, V. J., Rajavashisth, T. B., Gimbrone, M. A., Shin, W. S., & Liao, J. K. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118074 · Cited by 1,781
Nitric Oxide Is Responsible for Flow-Dependent Dilatation of Human Peripheral Conduit Arteries In Vivo
Joannidès, R., Haefeli, W. E., Linder, L., Richard, V. J., Bakkali, E. H., Thuillez, C., & Lüscher, T. F. (1995) · Circulation · doi:10.1161/01.cir.91.5.1314 · Cited by 1,622
Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase
Simoncini, T., Hafezi‐Moghadam, A., Brazil, D. P., Ley, K. F., Chin, W. W., & Liao, J. K. (2000) · Nature · doi:10.1038/35035131 · Cited by 1,436
Fatty Acids, Eicosanoids, and Hypolipidemic Agents Identified as Ligands of Peroxisome Proliferator-Activated Receptors by Coactivator-Dependent Receptor Ligand Assay
Krey, G. D., Braissant, O., L’Horset, F., Kalkhoven, E., Perroud, M., Parker, M. G., & Wahli, W. (1997) · Molecular Endocrinology · doi:10.1210/mend.11.6.0007 · Cited by 1,230

Show all 47 references

Research works printed but not linked: 10

10.1161/circ.98.19.2088 · DOI
10.1161/circ.99.24.3125 · DOI
10.1161/res.85.5.394 · DOI
10.1161/circ.103.2.207 · DOI
1995, Circulation, 92, 1314
1990, Biochem Int, 20, 445
1988, Nature, 323, 411
1998, J Pharmacol Exp Ther, 284, 751
10.1128/MCB.14.5.3130 · DOI
2003, J Neurosci, 16, 6264

Sorted by citations

PPARs: therapeutic targets for metabolic disease
Berger, J. P., Akiyama, T. E., & Meinke, P. T. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.03.003 · Cited by 716
An overview on biological mechanisms of PPARs
Kota, B. P., Huang, T. H.-W., & Roufogalis, B. D. (2004) · Pharmacological Research · doi:10.1016/j.phrs.2004.07.012 · Cited by 681
Inflammation in Hypertension
Xiao, L., & Harrison, D. G. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.01.013 · Cited by 557
Therapeutic roles of peroxisome proliferator-activated receptor agonists
Staels, B., & Fruchart, J.-C. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2460 · Cited by 646
Peroxisome Proliferator-Activated Receptors and Atherogenesis: Regulators of Gene Expression in Vascular Cells
Marx, N., Duez, H., Fruchart, J.-C., & Staels, B. (2004) · Circulation Research · doi:10.1161/01.res.0000127122.22685.0a · Cited by 501
Nitric oxide and atherosclerosis: An update
Claudio Napoli, A., de Nigris, F., Williams‐Ignarro, S., Pignalosa, O., Sica, V., & Ignarro, L. J. (2006) · Nitric Oxide · doi:10.1016/j.niox.2006.03.011 · Cited by 471
Thirty Years of Saying NO
Vanhoutte, P. M., Zhao, Y., Xu, A., & Leung, S. W. S. (2016) · Circulation Research · doi:10.1161/circresaha.116.306531 · Cited by 409
Peroxisome Proliferator-Activated Receptor Targets for the Treatment of Metabolic Diseases
Monsalve, F. A., Pyarasani, R. D., Delgado‐López, F., & Moore‐Carrasco, R. (2013) · Mediators of Inflammation · doi:10.1155/2013/549627 · Cited by 358
Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation
Du, X., Edelstein, D., Obici, S., Higham, N., Zou, M., & Brownlee, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci23354 · Cited by 351
Resveratrol prevents renal lipotoxicity and inhibits mesangial cell glucotoxicity in a manner dependent on the AMPK–SIRT1–PGC1α axis in db/db mice
Kim, M. Y., Lim, J. H., Youn, H. H., Hong, Y. A., Yang, K. S., Park, H., Chung, S., Koh, S. H., Shin, S. J., Choi, B. S., et al. (2012) · Diabetologia · doi:10.1007/s00125-012-2747-2 · Cited by 315
Role of branched-chain amino acid metabolism in the pathogenesis of obesity and type 2 diabetes-related metabolic disturbances BCAA metabolism in type 2 diabetes
Vanweert, F., Schrauwen, P., & Phielix, E. (2022) · Nutrition and Diabetes · doi:10.1038/s41387-022-00213-3 · Cited by 331
Inflammation in hypertension
Savoia, C., & Schiffrin, E. L. (2006) · Current Opinion in Internal Medicine · doi:10.1097/01.mnh.0000203189.57513.76 · Cited by 287
Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy
Grundy, S. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2005 · Cited by 294
Nitric oxide and pathogenic mechanisms involved in the development of vascular diseases
Napoli, C., & Ignarro, L. J. (2009) · Archives of Pharmacal Research · doi:10.1007/s12272-009-1801-1 · Cited by 281
PPARα in atherosclerosis and inflammation
Zandbergen, F. J., & Plutzky, J. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.04.021 · Cited by 219
PPARs and the Cardiovascular System
Hamblin, M., Chang, L., Fan, Y., Zhang, J., & Chen, Y. E. (2008) · Antioxidants and Redox Signaling · doi:10.1089/ars.2008.2280 · Cited by 210
Additive Beneficial Effects of Fenofibrate Combined With Atorvastatin in the Treatment of Combined Hyperlipidemia
Koh, K. K., Quon, M. J., Han, S. H., Chung, W., Ahn, J. Y., Seo, Y., Choi, I. S., & Shin, E. K. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.02.052 · Cited by 199
Peroxisome Proliferator-Activated Receptor (PPAR) in Metabolic Syndrome and Type 2 Diabetes Mellitus
Jay, M., & Ren, J. T. (2007) · Current Diabetes Reviews · doi:10.2174/157339907779802067 · Cited by 202
Statins: a new insight into their mechanisms of action and consequent pleiotropic effects.
Jasińska-Stroschein, M., Owczarek, J., & Orszulak–Michalak, D. (2007) · PubMed · Cited by 192
Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
Touyz, R., & Schiffrin, E. (2006) · Vascular pharmacology · doi:10.1016/j.vph.2005.11.014 · Cited by 158
Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease
Robinson, E., & Grieve, D. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.03.003 · Cited by 132
The year in atherothrombosis
Moreno, P., & Fuster, V. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.06.077 · Cited by 128
PPARs and other nuclear receptors in inflammation
RIZZO, G., & Fiorucci, S. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.03.012 · Cited by 128
Age-Associated Molecular Changes in the Kidney in Aged Mice
Lim, J. H., Kim, E. N., Kim, M. Y., Chung, S., Shin, S. J., Kim, H. W., Yang, C. W., Kim, Y., Chang, Y. S., Park, C. W., et al. (2012) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2012/171383 · Cited by 126
Fenofibrate Improves Renal Lipotoxicity through Activation of AMPK-PGC-1α in db/db Mice
Hong, Y. A., Lim, J. H., Kim, M. Y., Kim, T. W., Kim, Y., Yang, K. S., Park, H. S., Choi, S. R., Chung, S., Kim, H. W., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096147 · Cited by 121
PPAR-α activation protects the type 2 diabetic myocardium against ischemia-reperfusion injury: involvement of the PI3-Kinase/Akt and NO pathway
Bulhak, A., Jung, C., Östenson, C., Lundberg, J. O., Sjöquist, P.-O. B., & Pernow, J. (2009) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00394.2008 · Cited by 116
Endothelial cell dysfunction: can’t live with it, how to live without it
Goligorsky, M. S. (2005) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00333.2004 · Cited by 116
Peroxisome proliferator-activated receptors and cardiovascular remodeling
Schiffrin, E. L. (2004) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00677.2004 · Cited by 110
Integrative Proteomics and Targeted Transcriptomics Analyses in Cardiac Endothelial Cells Unravel Mechanisms of Long-Term Radiation-Induced Vascular Dysfunction
Azimzadeh, O., Sievert, W., Sarioglu, H., Merl‐Pham, J., Yentrapalli, R., Bakshi, M. V., Janik, D., Ueffing, M., Atkinson, M. J., Multhoff, G., et al. (2015) · Journal of Proteome Research · doi:10.1021/pr501141b · Cited by 112
Review article: therapeutic aspects of bile acid signalling in the gut‐liver axis
Simbrunner, B., Trauner, M., & Reiberger, T. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16602 · Cited by 108
Coagulation and atherothrombotic disease
Ajjan, R., & Grant, P. J. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.10.042 · Cited by 106
PPARα: an emerging therapeutic target in diabetic microvascular damage
Hiukka, A., Maranghi, M., Matikainen, N., & Taskinen, M.-R. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.89 · Cited by 103
Dehydroepiandrosterone Mimics Acute Actions of Insulin to Stimulate Production of Both Nitric Oxide and Endothelin 1 via Distinct Phosphatidylinositol 3-Kinase- and Mitogen-Activated Protein Kinase-Dependent Pathways in Vascular Endothelium
Formoso, G., Chen, H., Kim, J., Montagnani, M., Consoli, A., & Quon, M. J. (2005) · Molecular Endocrinology · doi:10.1210/me.2005-0266 · Cited by 99
Resveratrol and Its Metabolites Bind to PPARs
Calleri, E., Pochetti, G., Dossou, K. S. S., Laghezza, A., Montanari, R., Capelli, D., Prada, E., Loiodice, F., Massolini, G., Bernier, M., et al. (2014) · ChemBioChem · doi:10.1002/cbic.201300754 · Cited by 102
Fine metabolic regulation in ruminants via nutrient–gene interactions: saturated long-chain fatty acids increase expression of genes involved in lipid metabolism and immune response partly through PPAR-α activation
Bionaz, M., Thering, B. J., & Loor, J. J. (2011) · British Journal Of Nutrition · doi:10.1017/s0007114511002777 · Cited by 100
SIRT1 Antagonizes Oxidative Stress in Diabetic Vascular Complication
Meng, T., Qin, W., & Liu, B. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.568861 · Cited by 100
Beneficial Vascular and Metabolic Effects of Peroxisome Proliferator-Activated Receptor-α Activators
Han, S. H., Quon, M. J., & Koh, K. K. (2005) · Hypertension · doi:10.1161/01.hyp.0000187900.36455.4c · Cited by 98
Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men
Ryan, K. E., McCance, D. R., Powell, L., McMahon, R., & Trimble, E. R. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.11.007 · Cited by 94
PPARα activators upregulate eNOS activity and inhibit cytokine-induced NF-κB activation through AMP-activated protein kinase activation
Okayasu, T., Tomizawa, A., Suzuki, K., Manaka, K., & Hattori, Y. (2008) · Life Sciences · doi:10.1016/j.lfs.2008.02.002 · Cited by 93
Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes
KONES, R. J. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s37119 · Cited by 91
Does reversal of oxidative stress and inflammation provide vascular protection?
Koh, K. K., Oh, P. C., & Quon, M. J. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvn354 · Cited by 89
Fenofibrate increases high-density lipoprotein and sphingosine 1 phosphate concentrations limiting abdominal aortic aneurysm progression in a mouse model.
Krishna, S., Seto, S., Moxon, J., Rush, C., Walker, P., Norman, P., & Golledge, J. (2012) · American Journal of Pathology · doi:10.1016/j.ajpath.2012.04.015 · Cited by 86
Fenofibrate activates AMPK and increases eNOS phosphorylation in HUVEC
Murakami, H., Murakami, R., Kambe, F., Cao, X., Takahashi, R., Asai, T., Hirai, T., Numaguchi, Y., Okumura, K., Seo, H., et al. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.01.052 · Cited by 82
PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS: How Their Effects on Macrophages Can Lead to the Development of a New Drug Therapy Against Atherosclerosis
Li, A. C., & Palinski, W. (2005) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141247 · Cited by 77
Fenofibrate Improves Vascular Endothelial Function by Reducing Oxidative Stress While Increasing Endothelial Nitric Oxide Synthase in Healthy Normolipidemic Older Adults
Walker, A. E., Kaplon, R. E., Lucking, S. M. S., Russell, M. J., Eckel, R. H., & Seals, D. R. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.203661 · Cited by 76
Aldose reductase regulates hyperglycemia-induced HUVEC death via SIRT1/AMPK-α1/mTOR pathway
Pal, P. B., Sonowal, H., Shukla, K., Sk, S., & Ramana, K. V. (2019) · Journal of Molecular Endocrinology · doi:10.1530/jme-19-0080 · Cited by 76
The Positive Regulation of eNOS Signaling by PPAR Agonists in Cardiovascular Diseases
Maccallini, C., Mollica, A., & Amoroso, R. (2017) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-017-0220-9 · Cited by 62
Biology and Therapeutic Applications of Peroxisome Proliferator- Activated Receptors
P. Menendez-Gutierrez, M., Roszer, T., & Ricote, M. (2012) · Current Topics in Medicinal Chemistry · doi:10.2174/156802612799436669 · Cited by 62
Clofibrate PPARα Activation Reduces Oxidative Stress and Improves Ultrastructure and Ventricular Hemodynamics in No-flow Myocardial Ischemia
Ibarra-Lara, L., Hong, E., Soria‐Castro, E., Torres-Narváez, J. C., Pérez‐Severiano, F., del Valle‐Mondragón, L., Cervantes-Pérez, L. G., Ramírez-Ortega, M. D. C., Pastelín-Hernández, G. S., & Sánchez-Mendoza, A. (2012) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e31826216ed · Cited by 61
Protection against myocardial ischaemia/reperfusion injury by PPAR–α activation is related to production of nitric oxide and endothelin–1
Bulhak, A., Sjöquist, P.-O. B., Xu, C., Edvinsson, L. I., & Pernow, J. (2006) · Basic Research in Cardiology · doi:10.1007/s00395-005-0580-1 · Cited by 60
Endothelial dysfunction and reduced antioxidant protection in an animal model of the developmental origins of cardiovascular disease
Rodford, J. L., Torrens, C., Siow, R., Mann, G., Hanson, M., & Clough, G. (2008) · Journal of Physiology · doi:10.1113/jphysiol.2008.156976 · Cited by 58
Additive Beneficial Effects of Fenofibrate Combined With Candesartan in the Treatment of Hypertriglyceridemic Hypertensive Patients
Koh, K. K., Quon, M. J., Han, S. H., Chung, W., Ahn, J. Y., Kim, J., Lee, Y., & Shin, E. K. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1418 · Cited by 57
PPARα as a therapeutic target in inflammation-associated diseases
Gervois, P. P., & Mansouri, R. M. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.715633 · Cited by 54
Paullinia pinnata Extracts Rich in Polyphenols Promote Vascular Relaxation via Endothelium-dependent Mechanisms
Zamblé, A., Carpentier, M., Kandoussi, A., Şahpaz, S., Pétrault, O., Ouk, T., Hennuyer, N., Fruchart, J., Staels, B., Bordet, R., et al. (2006) · Journal of Cardiovascular Pharmacology · doi:10.1097/01.fjc.0000211734.53798.1d · Cited by 51
Curcuma oil ameliorates hyperlipidaemia and associated deleterious effects in golden Syrian hamsters
Singh, V., Jain, M. K., Misra, A., Khanna, V., Rana, M., Prakash, P., Malasoni, R., Dwivedi, A. K., Dikshit, M., & Barthwal, M. K. (2013) · British Journal Of Nutrition · doi:10.1017/s0007114512005363 · Cited by 51
Vascular and metabolic effects of treatment of combined hyperlipidemia: Focus on statins and fibrates
Koh, K. K., Quon, M. J., Rosenson, R. S., Chung, W., & Han, S. H. (2007) · International Journal of Cardiology · doi:10.1016/j.ijcard.2007.04.080 · Cited by 48
Curcumin inhibits TNFα-induced lectin-like oxidised LDL receptor-1 (LOX-1) expression and suppresses the inflammatory response in human umbilical vein endothelial cells (HUVECs) by an antioxidant mechanism
Lee, H.-S., Lee, M. J., Kim, H., Choi, S., Kim, J., Moon, H., & Park, W. (2010) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756360903555274 · Cited by 48
Pharmacological Utility of PPAR Modulation for Angiogenesis in Cardiovascular Disease
Wagner, N., & Wagner, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032345 · Cited by 48
Repeated and long-term treatment with physiological concentrations of resveratrol promotes NO production in vascular endothelial cells
Takahashi, S., & Nakashima, Y. (2011) · British Journal Of Nutrition · doi:10.1017/s0007114511003588 · Cited by 46
Plant polyphenols Morin and Quercetin rescue nitric oxide production in diabetic mouse aorta through distinct pathways
Taguchi, K., Tano, I., Kaneko, N., Matsumoto, T., & Kobayashi, T. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110463 · Cited by 46
Role of the Peroxisome Proliferator Activated Receptors in Hypertension
Fang, S., Livergood, M. C., Nakagawa, P., Wu, J., & Sigmund, C. D. (2021) · Circulation Research · doi:10.1161/circresaha.120.318062 · Cited by 46
Nitric Oxide-Releasing Platforms for Treating Cardiovascular Disease
He, M., Wang, D., Xu, Y., Jiang, F., Zheng, J., Feng, Y., Cao, J.-M., & Zhou, X. H. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071345 · Cited by 48
The peroxisome proliferator-activated receptor-α (PPAR-α) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats
Linz, W., Wohlfart, P., Baader, M., Breitschopf, K., Falk, E., Schäfer, H., Gerl, M., Kramer, W., & Rütten, H. (2009) · Acta Pharmacologica Sinica · doi:10.1038/aps.2009.58 · Cited by 44
Pleiotropic actions of fenofibrate on the heart
Balakumar, P., Rohilla, A., & Mahadevan, N. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.11.002 · Cited by 42
PPARα activation upregulates nephrin expression in human embryonic kidney epithelial cells and podocytes by a dual mechanism
Ren, S., Xin, C., Beck, K., Saleem, M. A., Mathieson, P. W., Pavenstädt, H., Pfeilschifter, J. M., & Huwiler, A. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.10.158 · Cited by 42
Fenofibrate improves endothelial function in the brachial artery and forearm resistance arterioles of statin-treated Type 2 diabetic patients
Hamilton, S. J., Chew, G. T., Davis, T. M. E., & Watts, G. F. (2010) · Clinical Science · doi:10.1042/cs20090568 · Cited by 42
Endothelial function, arterial stiffness and lipid lowering drugs
Τζιόμαλος, Κ., Athyros, V. G., Karagiannis, A. I., & Mikhailidis, D. P. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.9.1143 · Cited by 41
Fenofibrate and metabolic syndrome
T. Kraja, A., A. Province, M., J. Straka, R., M. Ordovas, J., B. Borecki, I., & K. Arnett, D. (2010) · Endocrine, Metabolic & Immune Disorders - Drug Targets · doi:10.2174/187153010791213047 · Cited by 40
“[102] reported that FF increases endothelial Nitric Oxide (NO) availability.”
Endothelial Cell Dysfunction
Davidge, S. T., de Groot, C. J. M., & Taylor, R. N. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-407866-6.00009-2 · Cited by 41
PPAR‐δ in Vascular Pathophysiology
Wang, N. (2008) · PPAR Research · doi:10.1155/2008/164163 · Cited by 39
PPARs in atherosclerosis: The spatial and temporal features from mechanism to druggable targets
Zheng, Y., Shao, M., Zheng, Y., Sun, W., Qin, S., Sun, Z., Zhu, L., Guan, Y., Wang, Q., Wang, Y., et al. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.03.020 · Cited by 41
Activation of PPARδ prevents endothelial dysfunction induced by overexpression of amyloid-β precursor protein
d’Uscio, L. V., Das, P., Santhanam, A. V. R., He, T., Younkin, S. G., & Katušić, Z. S. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvs266 · Cited by 33
Bilirubin bioconversion to urobilin in the gut-liver-kidney axis: A biomarker for insulin resistance in the Cardiovascular-Kidney-Metabolic (CKM) Syndrome
Kipp, Z. A., Badmus, O. O., Stec, D. E., Hall, B., & Hinds, T. D. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156081 · Cited by 35
Fenofibrate improves age-related endothelial dysfunction in rat resistance arteries
de Sotomayor, M. Á., Mingorance, C., & Andriantsitohaina, R. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.08.041 · Cited by 33
Exercise as medicine for COVID-19: On PPAR with emerging pharmacotherapy
Heffernan, K. S., Ranadive, S. M., & Jae, S. Y. (2020) · Medical Hypotheses · doi:10.1016/j.mehy.2020.110197 · Cited by 32
Involvement of the peroxisome proliferator-activated receptor (PPAR) alpha in vascular response of endocannabinoids in the bovine ophthalmic artery
Romano, M. R., & Lograno, M. D. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.02.049 · Cited by 32
Analysis of PPARα-dependent and PPARα-independent transcript regulation following fenofibrate treatment of human endothelial cells
Araki, H., Tamada, Y., Imoto, S., Dunmore, B., Sanders, D. A., Humphrey, S., Nagasaki, M., Doi, A., Nakanishi, Y., Yasuda, K., et al. (2009) · Angiogenesis · doi:10.1007/s10456-009-9142-8 · Cited by 32
Peroxisome Proliferator-Activated Receptors and Atherosclerosis
Šoškić, S., Dobutović, B., Sudar-Milovanovic, E. M., Obradovic, M. M., Nikolić, D., Zarić, B. L., Stojanović, S. Đ., Stokić, E., Mikhailidis, D. P., & Isenović, E. R. (2011) · Angiology · doi:10.1177/0003319711401012 · Cited by 32
PPARs: A Potential Target for a Disease-Modifying Strategy in Stroke
Ouk, T., Potey, C., Gautier, S., Bastide, M., Deplanque, D., Staels, B., Duriez, P., Leys, D., & Bordet, R. (2013) · Current Drug Targets · doi:10.2174/1389450111314070005 · Cited by 31
Endothelium as a Therapeutic Target in Diabetes Mellitus: From Basic Mechanisms to Clinical Practice
Tentolouris, A., Eleftheriadou, I., Tzeravini, E., Tsilingiris, D., Paschou, S. Α., Siasos, G., & Tentolouris, N. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190119154152 · Cited by 31
Fenofibrate Inhibits Endothelin-1 Expression by Peroxisome Proliferator–Activated Receptor α–Dependent and Independent Mechanisms in Human Endothelial Cells
Glineur, C., Gross, B. S., NEVE, B. P., Rommens, C., Chew, G. T., Martin‐Nizard, F., Rodríguez‐Pascual, F., Lamas, S., Watts, G. F., & Staels, B. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.300665 · Cited by 30
CTRP13 Preserves Endothelial Function by Targeting GTP Cyclohydrolase 1 in Diabetes
Wang, C., Chao, Y., Xu, W., Liang, M., Deng, S., Zhang, D., & Huang, K. (2019) · Diabetes · doi:10.2337/db19-0635 · Cited by 30
Dual PPAR α/γ Agonists: Promises and Pitfalls in Type 2 Diabetes
Ahmed, I., Furlong, K., Flood, J. J., Treat, V., & Goldstein, B. J. (2007) · American Journal of Therapeutics · doi:10.1097/01.mjt.0000212890.82339.8d · Cited by 30
Leukotriene B4-loaded microspheres: a new therapeutic strategy to modulate cell activation
Nicolete, R., Rius, C., Piqueras, L., Jose, P. J., Sorgi, C. A., Soares, E. G., Sanz, M., & Faccioli, L. H. (2008) · BMC Immunology · doi:10.1186/1471-2172-9-36 · Cited by 26
The Novel Role of Fenofibrate in Preventing Nicotine- and Sodium Arsenite-Induced Vascular Endothelial Dysfunction in the Rat
Kaur, J., Reddy, K., & Balakumar, P. (2010) · Cardiovascular Toxicology · doi:10.1007/s12012-010-9086-7 · Cited by 27
Fenofibrate Rescues Diabetes-Related Impairment of Ischemia-Mediated Angiogenesis by PPARα-Independent Modulation of Thioredoxin-Interacting Protein
Yuan, J. J., Tan, J. T. M., Rajamani, K., Solly, E. L., King, E. J., Lecce, L., Simpson, P. J. L., Lam, Y. T., Jenkins, A. J., Bursill, C. A., et al. (2019) · Diabetes · doi:10.2337/db17-0926 · Cited by 27
PPAR‐alpha: therapeutic role in diabetes‐related cardiovascular disease
CHENG, A. Y. Y., & Leiter, L. A. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00747.x · Cited by 27
Effect of a Peroxisome Proliferator–Activated Receptor-γ Agonist on Myocardial Blood Flow in Type 2 Diabetes
McMahon, G. T., Plutzky, J., Daher, E., Bhattacharyya, T., Grunberger, G., & DiCarli, M. F. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1145 · Cited by 26
Molecular Biological and Clinical Understanding of the Statin Residual Cardiovascular Disease Risk and Peroxisome Proliferator-Activated Receptor Alpha Agonists and Ezetimibe for Its Treatment
Yanai, H., Adachi, H., Hakoshima, M., & Katsuyama, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073418 · Cited by 25
Renoprotective Effects of Fenofibrate via Modulation of LKB1/AMPK mRNA Expression and Endothelial Dysfunction in a Rat Model of Diabetic Nephropathy
Al‐Rasheed, N. M., Al-Rasheed, N. M., Attia, H., Alamin, M. A., Al‐Ajmi, H. N., Hasan, I. H., Mohamad, R. A., & Sinjilawi, N. A.-A. (2015) · Pharmacology · doi:10.1159/000381190 · Cited by 26
Peroxisome Proliferator-Activated Receptor α Activation-Mediated Regulation of Endothelin-1 Production via Nitric Oxide and Protein Kinase C Signaling Pathways in Piglet Cerebral Microvascular Endothelial Cell Culture
Yakubu, M. A., Nsaif, R. H., & Oyekan, A. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.104992 · Cited by 25
Inflammation at the blood-brain barrier: The role of liver X receptors
de Wit, N. M., Vanmol, J., Kamermans, A., Hendriks, J. J. A., & de Vries, H. E. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.09.015 · Cited by 27
PPARα stimulation exerts a blood pressure lowering effect through different mechanisms in a time-dependent manner
Ibarra-Lara, L., Cervantes-Pérez, L. G., Pérez‐Severiano, F., del Valle‐Mondragón, L., Rubio-Ruiz, M. E., Soria‐Castro, E., Pastelín-Hernández, G. S., Sánchez-Aguilar, M., Martínez‐Lazcano, J. C., & Sánchez-Mendoza, A. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.10.039 · Cited by 25
The Role of Peroxisome Proliferator-Activated Receptors in Preeclampsia
Psilopatis, I., Vrettou, K., Fleckenstein, F. N., & Theocharis, S. E. (2023) · Cells · doi:10.3390/cells12040647 · Cited by 24
Effect of Berberine on PPARα/NO Activation in High Glucose- and Insulin-Induced Cardiomyocyte Hypertrophy
Wang, M., Wang, J., Tan, R., Wu, Q., Qiu, H., Yang, J., & Jiang, Q. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/285489 · Cited by 24
PPAR Activation: A New Target for the Treatment of Hypertension
Leibovitz, E., & Schiffrin, E. L. (2007) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318062153b · Cited by 24
An insight to treat cardiovascular diseases through phytochemicals targeting PPAR-α
Sharma, S., Sharma, D., Dhobi, M., Wang, D., & Tewari, D. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04755-7 · Cited by 23
Bile acid signaling in MASLD: From pathogenesis to therapeutic applications
Simbrunner, B., Paternostro, R., Reiberger, T., & Trauner, M. (2025) · Hepatology · doi:10.1097/hep.0000000000001539 · Cited by 30
Pretreatment with peroxysome proliferator-activated receptor α agonist fenofibrate protects endothelium in rabbit Escherichia coli endotoxin-induced shock
Wiel, É., Lebuffe, G., Robin, E., Gasan, G., Corseaux, D., Tavernier, B., Jude, B., Bordet, R., & Vallet, B. (2005) · Intensive Care Medicine · doi:10.1007/s00134-005-2730-1 · Cited by 22
Long-term fenofibrate treatment impairs endothelium-dependent dilation to acetylcholine by altering the cyclooxygenase pathway
BLANCORIVERO, J., MARQUEZRODAS, I., XAVIER, F., ARASLOPEZ, R., ARROYOVILLA, I., FERRER, M., & BALFAGON, G. (2007) · Cardiovascular Research · doi:10.1016/j.cardiores.2007.03.006 · Cited by 21

Authors: Goya, K., Sumitani, S., Xu, X., Kitamura, T., Yamamoto, H., Kurebayashi, S., Saito, H., Kouhara, H., Kasayama, S., & Kawase, I.
Affiliations: The University of Osaka (JP)
ORCID: Xu, Xin
Kitamura, Tetsuhiro
Yamamoto, Hiroyasu
Saito, Hiroshi
Kasayama, Soji
Kawase, Ichiro
Venue: Arteriosclerosis, Thrombosis, and Vascular Biology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2004-04
Volume: 24
Issue: 4
Pages: 658-663
ISSN: 1079-5642 (ISSN-L)
1524-4636
DOI: 10.1161/01.atv.0000118682.58708.78
OpenAlex: W2110733021
Cited by: 174
References: 47
Citations by year: 2026: 1 · 2025: 4 · 2024: 4 · 2023: 6 · 2022: 4 · 2021: 5 · 2020: 6 · 2019: 9 · 2017: 1 · 2016: 7 · 2015: 4 · 2014: 7 · 2013: 13 · 2012: 16
FWCI: 5.56
Type: journal article
Language: en
Open access: closed
Locations: Arteriosclerosis Thrombosis and Vascular Biology (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
Keywords: PPARα agonist, endothelial nitric oxide synthase, fenofibrate, bezafibrate, Wy-14,643, rosiglitazone, RU486, vascular endothelial cells, cardioprotection
MeSH terms: Rosiglitazone, Animals, Aorta, Bezafibrate, Cattle, Cells, Cultured, Dactinomycin, Endothelium, Vascular, Enzyme Induction, Half-Life, Nitric Oxide, Fenofibrate, Pyrimidines, RNA, Messenger, Transcription Factors, Transcription, Genetic, Transfection, Mifepristone, Gene Expression Regulation, Enzymologic, Receptors, Cytoplasmic and Nuclear, Nitric Oxide Synthase, Endothelial Cells, Thiazolidinediones, Nitric Oxide Synthase Type III

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Peroxisome Proliferator-Activated Receptor α Agonists Increase Nitric Oxide Synthase Expression in Vascular Endothelial Cells

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks